Founded Year
2017Stage
Corporate Majority | AcquiredValuation
$0000About BlackSwan Vascular
BlackSwan Vascula develops liquid embolic products for use in peripheral vascular applications. It offers product key differentiators including radiopacity, availability in two viscosities, reduced preparation time, and controlled delivery. The company was founded in 2017 and is based in Hayward, California. In April 2023, Grand Pharmaceutical acquired a majority stake in BlackSwan Vascular for $37.5M.
Missing: BlackSwan Vascular's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: BlackSwan Vascular's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest BlackSwan Vascular News
May 10, 2023
Grand Pharmaceutical Group Ltd. plans to acquire an 87.5% stake in Blackswan Vascular Inc., a company that develops liquid embolism for peripheral vascular applications, as it continues to expand its footprint in tumor intervention.
BlackSwan Vascular Frequently Asked Questions (FAQ)
When was BlackSwan Vascular founded?
BlackSwan Vascular was founded in 2017.
Where is BlackSwan Vascular's headquarters?
BlackSwan Vascular's headquarters is located at 709 Sandoval Way, Hayward.
What is BlackSwan Vascular's latest funding round?
BlackSwan Vascular's latest funding round is Corporate Majority.
Who are the investors of BlackSwan Vascular?
Investors of BlackSwan Vascular include Grand Pharmaceutical and Sirtex Medical.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.